TXP PHARMA
TXP is a biotech business that conducts research and develops medications that act as an agonist on melanocortin receptors to treat inflammatory and autoimmune illnesses.
TXP PHARMA
Industry:
Biotechnology Pharmaceutical
Founded:
2013-01-01
Address:
Baar, Zug, Switzerland
Country:
Switzerland
Status:
Active
Similar Organizations
Albior
Albior is a biotechnology company and performs research and development programs in the field of the intestinal microbiota.
Anapharm Bioanalytics
Anapharm Bioanalytics is a bioanalytical contract research organization that offers clinical and statistical services for clinical trials.
Farmagens Health Care
Farmagens Health Care specializes in biotechnological research and develops medicinal products dedicated to women's health and beauty.
Lonza
Lonza Group supplies products and services to pharmaceutical and agrochemical industries.
LPS-BioSciences
LPS-BioSciences is a biotechnical company that focuses on the research and development of vaccines, diagnostics and endotoxins.
NeuroTargets
NeuroTargets is a biotechnology company that researches and develops drugs for the treatment of neurological diseases.
Roche Diagnostics Belgium
Roche Diagnostics Belgium is a biotechnology company focused on the research and development of pharmaceuticals and diagnostics.
More informations about "TXP Pharma"
TXP Pharma Company Profile 2024: Valuation, Investors
TXP Pharma General Information Description. Operator of a biotech company focused on autoimmune and inflammatory diseases. The company researches and develops …See details»
SynAct Pharma completes the acquisition of TXP Pharma
“Through the closing of the acquisition of TXP Pharma, we are now in position of a pipeline which in addition to our very promising lead candidate drug, AP1189, consists of an additional clinical …See details»
SynAct Pharma to make strategic acquisition of Swiss biotech …
Dec 12, 2022 SynAct Pharma AB (publ) (“SynAct” or the “Company”) today announced that the Company has entered into a conditional agreement on acquisition of TXP Pharma AG (“TXP”), …See details»
SynAct Pharma’s acquisition of TXP Pharma concluded
TXP Pharma - Products, Competitors, Financials, Employees, …
Dec 13, 2022 About TXP Pharma. TXP Pharma operates as a biotech company. It focuses on researching and developing pharmaceutical drugs for the treatment of autoimmune and …See details»
SynAct Pharma completes the acquisition of TXP Pharma
SynAct Pharma AB (publ) (“SynAct” or the “Company”) has today completed the acquisition of all shares in the Swiss-incorporated biotech company TXP Pharma AG (“TXP”) that SynAct …See details»
TXP Pharma AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TXP Pharma AG of Baar, ZUG. Get the latest business insights from Dun & Bradstreet.See details»
TXP Pharma - Drug pipelines, Patents, Clinical trials - Synapse
Explore TXP Pharma with its drug pipeline, therapeutic area, technology platform, . Explore TXP Pharma with its drug pipeline, therapeutic area, technology platform, . Biomedical products. …See details»
SynAct Pharma acquires TXP Pharma - 2022-12-12 - Crunchbase
Dec 12, 2022 TXP Pharma TXP is a biotech business that conducts research and develops medications that act as an agonist on melanocortin receptors. Acquiring Organization:See details»
TXP Pharma - Company Profile - Tracxn
Oct 20, 2024 TXP Pharma ranks 340th among 341 active competitors. 135 of its competitors are funded while 84 have exited. Overall, TXP Pharma and its competitors have raised over …See details»
SynAct acquires TXP Pharma and carries out a directed share issue
Dec 12, 2022 In conjunction with the acquisition of TXP Pharma the board of directors of SynAct Pharma has decided to carry out a directed share issue of 1,277,954 shares at a subscription …See details»
TXP-35 - Drug Targets, Indications, Patents - Synapse
Nov 9, 2024 TXP-35, Initially developed by SynAct Pharma AB, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Immune System Diseases,Other Diseases, Active …See details»
SynAct Pharma completes the acquisition of TXP Pharma
SynAct Pharma AB (publ) (“SynAct” or the “Company”) has today completed the acquisition of all shares in the Swiss-incorporated biotech company TXP Pharma AG (“TXP”) that SynAct …See details»
TXP Pharma - Tech Stack, Apps, Patents & Trademarks - Crunchbase
TXP is a biotech business that conducts research and develops medications that act as an agonist on melanocortin receptors. Search Crunchbase. ... The intellectual property of TXP …See details»
SynAct Pharma completes the acquisition of TXP Pharma
Jan 16, 2023 “Through the closing of the acquisition of TXP Pharma, we are now in position of a pipeline which in addition to our very promising lead candidate drug, AP1189, consists of an …See details»
SynAct Pharma to make strategic acquisition of Swiss biotech …
Dec 12, 2022 SynAct Pharma AB (publ) (“SynAct” or the “Company”) today announced that the Company has entered into a conditional agreement on acquisition of TXP Pharma AG (“TXP”), …See details»
Canadian health plans, pharma firm agree on terms to fund costly ...
1 day ago An organization representing Canada's public drug plans has come to a deal with a pharmaceutical company over a cutting-edge means of treating prostate cancer, bringing …See details»
SynAct strengthens its patent portfolio – SynAct Pharma
Mar 23, 2023 SynAct Pharma AB (publ) (“SynAct”) today announced that its recently acquired affiliate, TXP Pharma AG (“TXP”), was granted a patent in Canada related to “Alpha- and …See details»
TXP-11 - Drug Targets, Indications, Patents - Synapse - Patsnap
TXP-11, Initially developed by SynAct Pharma AB, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Other Diseases, Active Indication: Multiple Organ Failure, …See details»
Editor’s (re)View: Novo Holdings’ $16.5B Catalent buyout is the top ...
1 day ago Editor’s (re)View: Novo Holdings’ $16.5B Catalent buyout is the top pharma manufacturing story of 2024 Dec. 20, 2024 The acquisition, which took the global contract …See details»